Abstract
During the COVID-19 pandemic, cancer patients became reluctant to come to the hospital, receive cancer treatment, and were willing to interrupt or postpone treatment due to concerns about infection. The purpose of this study was to discuss effective treatment strategy decision making support for cancer patients by nurses recognized during the COVID-19 pandemic. The study population comprised nurse of decision-making support at cancer care during COVID-19 from May to July 2021 at 49 the cancer care center hospitals were established in each prefecture, who had engaged 50% of their nursing care provided to patients with cancer.
Data were collected on treatment strategy decision-making support using an online cross-sectional survey. Factors that influenced patients’ decision-making were identified using multivariable logistic regression analysis. A total of 182 (25.0%) were nurses engaged in decision making were enrolled in this study. Factors that influenced patients’ decision to receive treatment to their satisfaction were their resignation or compromise in accepting the decision due to the pandemic (odds ratio [OR] 0.44 (95% CI [0.22, 0.87]), videoconference follow-up (OR 0.17, 95% Cl [0.04, 0.66]), and infection prevention information provision (OR 3.82, 95% Cl [1.54,9.46]). Factors influencing patients’ decision to give up and accept the doctor’s recommendation even though they were not convinced included fear of disease progression (OR 2.51, 95% Cl [1.21, 5.22]), anger at not receiving the treatment they desired (OR 2.48, 95% Cl [1.17, 5.27]), and compromise with the pandemic situation (OR 3.15, 95% Cl [1.53, 6.50]). The factor that influenced patients’ continued treatment even though they were not convinced included the nurse listened to the patients’ thoughts (OR 0.07, 95% Cl [0.01, 0.51]). Treatment decision support of patients with cancer during COVID-19 included lifestyle guidance to prevent the spread of infection and listening to their concerns to help them find meaning in their choices.
Competing Interest Statement
The authors have declared that no competing interests exist.
Funding Statement
The author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was reviewed and approved by the Ethics Committee Tohoku University Graduate School of Medicine (Approval No. 2020-1-353). Informed consent was considered to be provided upon the completion of the online survey and to extend to the registration of the results. Responses to the survey were handled anonymously.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Not Applicable
Data Availability
All relevant data are within the manuscript and its Supporting Information files.
